The FDA comments in the CRL relate to proposed labelling language, not safety, Astellas said in a press release.

The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial. OPUVIZ is a biosimilar ...

The annual meeting, held in Chicago, Illinois, featured new data and best practices for patient-centered care. The American Academy of Ophthalmology (AAO) held its annual meeting at McCormick Place in ...

The European Commission (EC) granted marketing authorization for Afqlir (aflibercept), which is a 2 mg vial kit and pre-filled syringe for intravitreal injection. This is a biosimilar to reference ...

This merger creates an innovative biotechnology company with a broader focus in the advancement of multiple disease therapies. Akari Therapeutics, Plc has completed of the merger of Akari Therapeutics ...

VEGF-A therapy has revolutionized treatment and visual outcomes for patients with neovascular age-related macular degeneration (nAMD). Ranibizumab, the first anti–VEGF-A agent to be FDA approved, was ...

This drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related macular degeneration (nAMD). The US FDA has cleared an investigational new ...

Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative (MTM Vision) have begun what is expected to be a long-term collaboration. This announcement establishes Boehringer as the first ...

Although intravitreal injections are a safe and effective form of drug delivery, the need for frequent injections and the corresponding disruptions to patients’ lives can pose a significant treatment ...

PST-611 is a first in class non-viral vectorized therapy for the treatment of dry AMD/GA coding for human transferrin. PulseSight Therapeutics SAS presented new data on its lead program PST-611, a DNA ...

Ferhina S. Ali, MD, MPH, presenting at the OSN New York Retina meeting, discussed advances in next-generation anti-VEGF therapies, focusing on real-world data compared with clinical trial outcomes.